FDA Grants Rare Pediatric Disease Designation to Sensorion’s OTOF-GT for the Treatment of Otoferlin Gene-Mediated Hearing Loss

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to the Company’s lead therapy gene candidate, OTOF-GT, a gene therapy intended…

Read More
sensorion

Sensorion Announces Approval to Initiate Amended Phase 2a Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage  biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that the initiation of a Proof of Concept (PoC) clinical trial of SENS-401 (Arazasetron) in patients with Cisplatin-Induced Ototoxicity (CIO) has…

Read More
cochlear sensorion sens-401

First Patient Enrolled in Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation

MONTPELLIER, FRANCE — Sensorion (FR0012596468 – ALSEN), a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced that the first patient has been enrolled in its proof-of-concept clinical trial of SENS-401 (Arazasetron) in patients scheduled for cochlear implantation.…

Read More
sensorion

Sensorion Receives Positive Opinion for Orphan Drug Designation for OTOF-GT from the European Medicine Agency

MONTPELLIER, FRANCE – Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage  biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion on Sensorion’s application for Orphan…

Read More
sensorion

Sensorion Provides Update on SENS-401 in Sudden Sensorineural Hearing Loss

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today provided an update following supplementary analysis of the 115-patient Phase 2 AUDIBLE-S study of SENS-401 for the treatment of sudden sensorineural hearing loss (SSNHL). As…

Read More
sensorion

Sensorion Provides Updates on SENS-401 Phase 2 Trial in Sudden Sensorineural Hearing Loss

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today reports results from the 115-patient Phase 2 AUDIBLE-S study of SENS-401 (Arazasetron), for the treatment of sudden sensorineural hearing loss (SSNHL). SENS-401 was found to…

Read More
sensorion

Sensorion Appoints Aniz Girach as Independent Board Member

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, has announced that Aniz Girach, MD, is joining the Board of directors as an independent Board member. The appointment is effective following the Board meeting, which took place on January…

Read More
sensorion sonova aging hearing loss study

Sensorion and Sonova Sign Strategic Research Collaboration

MONTPELLIER, FRANCE — Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage biotech company specializing in the development of novel therapies to restore, treat, and prevent hearing related disorders, and hearing-care industry leader Sonova (SWX:SOON), have signed a multi-year strategic collaboration with the aim of introducing genetic analysis to the routine diagnosis of progressive hearing loss in adults,…

Read More
cochlear sensorion sens-401

Sensorion and Cochlear to Begin Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation

MONTPELLIER, FRANCE & SYDNEY, AUSTRALIA — Sensorion, a pioneering clinical-stage biotechnology startup specializing in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and Cochlear Limited, the global leader in implantable hearing solutions, announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401…

Read More
sensorion

Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer

MONTPELLIER, FRANCE — Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as…

Read More